Germline genetic biomarkers to stratify patients for personalized radiation treatment

• DOI: 10.1186/s12967-022-03561-x
• Publication Date: 2022-08-12T07:03:07Z
• Authors: Ida Deichaite; Austin Hopper; Lena Krockenberger; Timothy J. Sears; Leisa Sutton; Xenia Ray; Andrew Sharabi; Ami Navon; Parag Sanghvi; Hannah Carter; Vitali Moiseenko
• Keywords: Personalized Medicine

Abstract Background Precision medicine incorporating genetic profiling is becoming a standard of care in medical oncology. However, the field radiation oncology there limited use and impact germline biomarkers on radiosensitivity, radioresistance, or patient outcomes after therapy poorly understood. In HNSCC, toxicity associated with treatment can cause delays early cessation which has been worse outcomes. Identifying potential help predict toxicity, as well response to treatment, significant interest. Methods Patients HNSCC who received RT underwent next generation sequencing somatic tumor samples, transcriptome RNA-seq matched normal tissue samples were included. then grouped by propensity towards increased late vs. (Group A) those without B), assessed CTCAE v5.0. The groups analyzed for association specific variants clinical Results this study we 37 patients correlation between toxicity. We observed that TSC2, HLA-A, TET2, GEN1, NCOR2 other significantly long term toxicities. 34 treated curative intent evaluated Group A had improved overall survival rates locoregional recurrence metastatic disease. Specific included FANCD2, PPP1R15A, while HLA-A GEN1 not correlated recurrence. group five HLA-DMA/HLA-DMB was only found B higher risk Conclusions This indicates may have utility predicting deserve further investigation precision approaches.